Date: March, 2<sup>nd</sup>, 2023 Your Name: Sehhoon Park Manuscript Title: Real-world clinical evidence of lazertinib use in acquired EGFR T790M mutated non-small cell lung cancer Manuscript number (if known):\_\_\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	V None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	V None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	V None	
4	Consulting fees	V None	

5    Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events    V None      6    Payment for expert testimony    V None      7    Support for attending meetings and/or travel    V None      8    Patents planned, issued or pending    V None      9    Participation on a Data    V None				
speakers bureaus, manuscript writing or educational events    V    None      6    Payment for expert testimony    V    None      7    Support for attending meetings and/or travel    V    None      8    Patents planned, issued or pending    V    None      9    Participation on a Data    V    None	5		V None	
manuscript writing or educational events    V    None      6    Payment for expert testimony    V    None      7    Support for attending meetings and/or travel    V    None      8    Patents planned, issued or pending    V    None      9    Participation on a Data    V    None				
educational events    V None      6    Payment for expert testimony    V None      7    Support for attending meetings and/or travel    V None      8    Patents planned, issued or pending    V None      9    Participation on a Data    V None				
6    Payment for expert testimony    V None      7    Support for attending meetings and/or travel    V None      8    Patents planned, issued or pending    V None      9    Participation on a Data    V None				
testimony				
7    Support for attending meetings and/or travel    V None      8    Patents planned, issued or pending    V None      9    Participation on a Data    V None	6		V None	
meetings and/or travel		testimony		
meetings and/or travel	-			
pending	/		V None	
pending				
pending				
9  Participation on a Data  V None	8	Patents planned, issued or	V None	
		pending		
	9	Participation on a Data	V None	
		Safety Monitoring Board or		
Advisory Board				
10 Leadership or fiduciary role V None	10		V None	
in other board, society,		-		
committee or advocacy		-		
group, paid or unpaid				
11  Stock or stock options  V None	11	Stock or stock options	V None	
	10			
12 Receipt of equipment, V None	12		v None	
materials, drugs, medical writing, gifts or other				
services				
13 Other financial or non- V None	13		V None	
financial interests	15			

None

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Date: March, 2<sup>nd</sup>, 2023 Your Name: Hyun-Ae Jung Manuscript Title: Real-world clinical evidence of lazertinib use in acquired EGFR T790M mutated non-small cell lung cancer Manuscript number (if known):\_\_\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	V None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	V None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	V None	
4	Consulting fees	V None	

5    Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events    V None      6    Payment for expert testimony    V None      7    Support for attending meetings and/or travel    V None      8    Patents planned, issued or pending    V None      9    Participation on a Data    V None				
speakers bureaus, manuscript writing or educational events    V    None      6    Payment for expert testimony    V    None      7    Support for attending meetings and/or travel    V    None      8    Patents planned, issued or pending    V    None      9    Participation on a Data    V    None	5		V None	
manuscript writing or educational events    V    None      6    Payment for expert testimony    V    None      7    Support for attending meetings and/or travel    V    None      8    Patents planned, issued or pending    V    None      9    Participation on a Data    V    None				
educational events    V None      6    Payment for expert testimony    V None      7    Support for attending meetings and/or travel    V None      8    Patents planned, issued or pending    V None      9    Participation on a Data    V None				
6    Payment for expert testimony    V None      7    Support for attending meetings and/or travel    V None      8    Patents planned, issued or pending    V None      9    Participation on a Data    V None				
testimony				
7    Support for attending meetings and/or travel    V None      8    Patents planned, issued or pending    V None      9    Participation on a Data    V None	6		V None	
meetings and/or travel		testimony		
meetings and/or travel	-			
pending	/		V None	
pending				
pending				
9  Participation on a Data  V None	8	Patents planned, issued or	V None	
		pending		
	9	Participation on a Data	V None	
		Safety Monitoring Board or		
Advisory Board				
10 Leadership or fiduciary role V None	10		V None	
in other board, society,		-		
committee or advocacy		-		
group, paid or unpaid				
11  Stock or stock options  V None	11	Stock or stock options	V None	
	10			
12 Receipt of equipment, V None	12		v None	
materials, drugs, medical writing, gifts or other				
services				
13 Other financial or non- V None	13		V None	
financial interests	15			

None

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this

Date: March, 2<sup>nd</sup>, 2023 Your Name: Se-Hoon Lee Manuscript Title: Real-world clinical evidence of lazertinib use in acquired EGFR T790M mutated non-small cell lung cancer Manuscript number (if known):\_\_\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	V None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	V None	
3	Royalties or licenses	V None	
4	Consulting fees	V None	

5    Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events    V None      6    Payment for expert testimony    V None      7    Support for attending meetings and/or travel    V None      8    Patents planned, issued or pending    V None      9    Participation on a Data    V None				
speakers bureaus, manuscript writing or educational events    V    None      6    Payment for expert testimony    V    None      7    Support for attending meetings and/or travel    V    None      8    Patents planned, issued or pending    V    None      9    Participation on a Data    V    None	5		V None	
manuscript writing or educational events    V    None      6    Payment for expert testimony    V    None      7    Support for attending meetings and/or travel    V    None      8    Patents planned, issued or pending    V    None      9    Participation on a Data    V    None				
educational events    V None      6    Payment for expert testimony    V None      7    Support for attending meetings and/or travel    V None      8    Patents planned, issued or pending    V None      9    Participation on a Data    V None				
6    Payment for expert testimony    V None      7    Support for attending meetings and/or travel    V None      8    Patents planned, issued or pending    V None      9    Participation on a Data    V None				
testimony				
7    Support for attending meetings and/or travel    V None      8    Patents planned, issued or pending    V None      9    Participation on a Data    V None	6		V None	
meetings and/or travel		testimony		
meetings and/or travel	-			
pending	/		V None	
pending				
pending				
9  Participation on a Data  V None	8	Patents planned, issued or	V None	
		pending		
	9	Participation on a Data	V None	
		Safety Monitoring Board or		
Advisory Board				
10 Leadership or fiduciary role V None	10		V None	
in other board, society,		-		
committee or advocacy		-		
group, paid or unpaid				
11  Stock or stock options  V None	11	Stock or stock options	V None	
	10			
12 Receipt of equipment, V None	12		v None	
materials, drugs, medical writing, gifts or other				
services				
13 Other financial or non- V None	13		V None	
financial interests	15			

None

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this

Date: March, 2<sup>nd</sup>, 2023 Your Name: Jin Seok Ahn Manuscript Title: Real-world clinical evidence of lazertinib use in acquired EGFR T790M mutated non-small cell lung cancer Manuscript number (if known):\_\_\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	V None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	V None	
3	Royalties or licenses	V None	
4	Consulting fees	V None	

5    Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events    V None      6    Payment for expert testimony    V None      7    Support for attending meetings and/or travel    V None      8    Patents planned, issued or pending    V None      9    Participation on a Data    V None				
speakers bureaus, manuscript writing or educational events    V    None      6    Payment for expert testimony    V    None      7    Support for attending meetings and/or travel    V    None      8    Patents planned, issued or pending    V    None      9    Participation on a Data    V    None	5		V None	
manuscript writing or educational events    V    None      6    Payment for expert testimony    V    None      7    Support for attending meetings and/or travel    V    None      8    Patents planned, issued or pending    V    None      9    Participation on a Data    V    None				
educational events    V None      6    Payment for expert testimony    V None      7    Support for attending meetings and/or travel    V None      8    Patents planned, issued or pending    V None      9    Participation on a Data    V None				
6    Payment for expert testimony    V None      7    Support for attending meetings and/or travel    V None      8    Patents planned, issued or pending    V None      9    Participation on a Data    V None				
testimony				
7    Support for attending meetings and/or travel    V None      8    Patents planned, issued or pending    V None      9    Participation on a Data    V None	6		V None	
meetings and/or travel		testimony		
meetings and/or travel	-			
pending	/		V None	
pending				
pending				
9  Participation on a Data  V None	8	Patents planned, issued or	V None	
		pending		
	9	Participation on a Data	V None	
		Safety Monitoring Board or		
Advisory Board				
10 Leadership or fiduciary role V None	10		V None	
in other board, society,		-		
committee or advocacy		-		
group, paid or unpaid				
11  Stock or stock options  V None	11	Stock or stock options	V None	
	10			
12 Receipt of equipment, V None	12		v None	
materials, drugs, medical writing, gifts or other				
services				
13 Other financial or non- V None	13		V None	
financial interests	15			

None

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this

Date: March, 2<sup>nd</sup>, 2023 Your Name: Myung-Ju Ahn Manuscript Title: Real-world clinical evidence of lazertinib use in acquired EGFR T790M mutated non-small cell lung cancer Manuscript number (if known):\_\_\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	V None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	V None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	V None	
4	Consulting fees	V None	

5    Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events    V None      6    Payment for expert testimony    V None      7    Support for attending meetings and/or travel    V None      8    Patents planned, issued or pending    V None      9    Participation on a Data    V None				
speakers bureaus, manuscript writing or educational events    V    None      6    Payment for expert testimony    V    None      7    Support for attending meetings and/or travel    V    None      8    Patents planned, issued or pending    V    None      9    Participation on a Data    V    None	5		V None	
manuscript writing or educational events    V    None      6    Payment for expert testimony    V    None      7    Support for attending meetings and/or travel    V    None      8    Patents planned, issued or pending    V    None      9    Participation on a Data    V    None				
educational events    V None      6    Payment for expert testimony    V None      7    Support for attending meetings and/or travel    V None      8    Patents planned, issued or pending    V None      9    Participation on a Data    V None				
6    Payment for expert testimony    V None      7    Support for attending meetings and/or travel    V None      8    Patents planned, issued or pending    V None      9    Participation on a Data    V None				
testimony				
7    Support for attending meetings and/or travel    V None      8    Patents planned, issued or pending    V None      9    Participation on a Data    V None	6		V None	
meetings and/or travel		testimony		
meetings and/or travel	-			
pending	/		V None	
pending				
pending				
9  Participation on a Data  V None	8	Patents planned, issued or	V None	
		pending		
	9	Participation on a Data	V None	
		Safety Monitoring Board or		
Advisory Board				
10 Leadership or fiduciary role V None	10		V None	
in other board, society,		-		
committee or advocacy		-		
group, paid or unpaid				
11  Stock or stock options  V None	11	Stock or stock options	V None	
	10			
12 Receipt of equipment, V None	12		v None	
materials, drugs, medical writing, gifts or other				
services				
13 Other financial or non- V None	13		V None	
financial interests	15			

None

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this

Date: March, 2<sup>nd</sup>, 2023 Your Name: Jong-Mu Sun Manuscript Title: Real-world clinical evidence of lazertinib use in acquired EGFR T790M mutated non-small cell lung cancer Manuscript number (if known):\_\_\_\_\_

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	V None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	V None	
3	Royalties or licenses	V None	
4	Consulting fees	V None	

5    Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events    V None      6    Payment for expert testimony    V None      7    Support for attending meetings and/or travel    V None      8    Patents planned, issued or pending    V None      9    Participation on a Data    V None				
speakers bureaus, manuscript writing or educational events    V    None      6    Payment for expert testimony    V    None      7    Support for attending meetings and/or travel    V    None      8    Patents planned, issued or pending    V    None      9    Participation on a Data    V    None	5		V None	
manuscript writing or educational events    V    None      6    Payment for expert testimony    V    None      7    Support for attending meetings and/or travel    V    None      8    Patents planned, issued or pending    V    None      9    Participation on a Data    V    None				
educational events    V None      6    Payment for expert testimony    V None      7    Support for attending meetings and/or travel    V None      8    Patents planned, issued or pending    V None      9    Participation on a Data    V None				
6    Payment for expert testimony    V None      7    Support for attending meetings and/or travel    V None      8    Patents planned, issued or pending    V None      9    Participation on a Data    V None				
testimony				
7    Support for attending meetings and/or travel    V None      8    Patents planned, issued or pending    V None      9    Participation on a Data    V None	6		V None	
meetings and/or travel		testimony		
meetings and/or travel	-			
pending	/		V None	
pending				
pending				
9  Participation on a Data  V None	8	Patents planned, issued or	V None	
		pending		
	9	Participation on a Data	V None	
		Safety Monitoring Board or		
Advisory Board				
10 Leadership or fiduciary role V None	10		V None	
in other board, society,		-		
committee or advocacy		-		
group, paid or unpaid				
11  Stock or stock options  V None	11	Stock or stock options	V None	
	10			
12 Receipt of equipment, V None	12		v None	
materials, drugs, medical writing, gifts or other				
services				
13 Other financial or non- V None	13		V None	
financial interests	15			

None

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this